12 Stunden Investment-Webinar mit Top-Experten - kostenlos inkl. Aufzeichnung. Hier anmelden.

Sanofi Aktie

Kaufen Kaufen Verkaufen Verkaufen

Sanofi Aktien-Sparplan Sanofi Aktien-Sparplan

99,48 EUR -1,32 EUR -1,31 %

11:15:02

STU

100,70 EUR -0,74 EUR -0,73 %

09:05:23

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.127,50 Mrd. EUR

KGV20,81Div. Rendite4,19%

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

Sortieren:Datum Meistgelesen

27.09.24GlobeNewswirePress Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

27.09.24GlobeNewswirePress Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

26.09.24GlobeNewswirePress Release: Availability of the Q3 2024 Aide mémoire

WerbungSanofi-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

21.09.24GlobeNewswirePress Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans

20.09.24GlobeNewswirePress Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

20.09.24EN, Sanofi-AventisPress Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

20.09.24GlobeNewswirePress Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

20.09.24EN, Sanofi-AventisPress Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

16.09.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - August 2024

12.09.24GlobeNewswirePress Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

12.09.24EN, Sanofi-AventisPress Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

11.09.24GlobeNewswirePress Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

11.09.24EN, Sanofi-AventisPress Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

11.09.24GlobeNewswirePress Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

11.09.24EN, Sanofi-AventisPress Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

10.09.24EN, Sanofi-AventisMedia Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.